First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations
Sunvozertinib demonstrates superior progression‑free survival and a comparable safety profile as first‑line therapy for advanced non‑small‑cell lung cancer (NSCLC) patients with EGFR exon 20 insertion mutations compared with standard carboplatin–pemetrexed chemotherapy.
Background: Sunvozertinib has received accelerated approval for use in later lines of therapy in patients with advanced NSCLC harboring EGFR exon 20 insertion mutations. Data on its efficacy and safety in the first‑line setting were lacking. Methods: In a phase 3, international, randomized (1:1) trial, 324 patients with advanced nonsquamous NSCLC and EGFR exon 20 insertions were assigned to receive either sunvozertinib or standard carboplatin‑pemetrexed chemotherapy. The primary endpoint was progression‑free survival (PFS) assessed by blinded independent central review, with crossover to sunvozertinib allowed after confirmed disease progression. Secondary endpoints included overall survival, investigator‑assessed PFS, objective response rate, tumor‑size change, and duration of response. Results: Sunvozertinib produced a significantly longer median PFS compared with chemotherapy (10.3 vs. 7.5 months; HR 0.65; 95% CI 0.50–0.85; P < 0.001). At 12 months, PFS rates were 46.1 % versus 26.7 %. Objective response rates were 58.9 % versus 31.1 %, with median best tumor‑size reduction of –42.1 % versus –24.7 %. Median duration of response was 11.2 months versus 7.1 months. Grade 3 or higher adverse events occurred in 75.5 % of the sunvozertinib group and 56.7 % of the chemotherapy group; the most common grade ≥ 3 events were increased serum creatine kinase, diarrhea, and anemia. No drug‑related deaths were reported. Conclusions: Sunvozertinib shows superior efficacy and manageable toxicity as first‑line therapy for advanced NSCLC with EGFR exon 20 insertions. ClinicalTrials.gov identifier: NCT05668988.
The results provide evidence that targeting EGFR exon 20 insertions with sunvozertinib offers a more effective first‑line treatment option for a historically hard‑to‑treat subset of NSCLC patients, potentially improving progression‑free survival and objective response rates while maintaining an acceptable safety profile.
Evidence level: Irányelv / elfogadott gyakorlat. Magas szintű klinikai elfogadottság.
Related signals
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT